8-K: BioCryst Reports Strong Q3 2024 Results, Raises Full-Year Revenue Guidance

BioCryst Pharmaceuticals announced a strong third quarter with significant revenue growth for ORLADEYO, leading to increased full-year revenue guidance and advancements in their pipeline.

Summary

• BioCryst Pharmaceuticals reported its financial results for the third quarter of 2024, showing a 35.1 percent increase in total revenue year-over-year, reaching $117.1 million.
• ORLADEYO net revenue was $116.3 million, a 35.7 percent increase compared to the same quarter last year.
• The company has adjusted its full-year 2024 ORLADEYO revenue guidance to $430-$435 million and introduced total product revenue guidance of $443-$448 million, including revenue from RAPIVAB.
• BioCryst generated a GAAP operating profit of $7.7 million in the third quarter, and a non-GAAP operating profit of $24.9 million.
• The company's research and development expenses decreased by 12.4 percent year-over-year to $41.1 million, while selling, general, and administrative expenses increased by 28.7 percent to $65.1 million.
• BioCryst's cash, cash equivalents, restricted cash, and investments totaled $351.7 million at the end of September 2024.
• The company expects to achieve a full-year operating profit in 2024, approach quarterly positive earnings per share and positive cash flow in the second half of 2025, and be profitable on an EPS basis with positive cash flow for the full year 2026 without raising additional funds.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased guidance, and progress in the pipeline. The company's move towards profitability and positive cash flow further supports this positive outlook.

Positives

• ORLADEYO sales are experiencing strong growth, with a 35.7 percent increase in revenue year-over-year.
• The company is now generating a GAAP operating profit, indicating improved financial performance.
• The pipeline is progressing with BCX17725 entering clinical trials and avoralstat nearing clinical trials.
• The company has a strong cash position of $351.7 million.
• BioCryst expects to achieve full-year operating profit in 2024 and be profitable on an EPS basis with positive cash flow for the full year 2026 without raising additional funds.
• Patient demand for ORLADEYO remains robust, supporting the company's growth trajectory.

Negatives

• Selling, general, and administrative expenses increased by 28.7 percent year-over-year.
• The company reported a net loss of $14.0 million for the third quarter of 2024.
• Cash, cash equivalents, restricted cash and investments decreased from $399.2 million at September 30, 2023 to $351.7 million at September 30, 2024.

Risks

• The company's ability to successfully commercialize ORLADEYO and achieve sustained market acceptance is a risk.
• Clinical trials for pipeline products may not have positive results or may take longer than expected.
• Regulatory approvals for product candidates may be delayed or not granted.
• The company's financial projections may not be met due to market factors or operational challenges.
• The company faces risks related to international expansion and competition.

Future Outlook

BioCryst anticipates achieving full-year operating profit in 2024, approaching quarterly positive earnings per share and positive cash flow in the second half of 2025, and being profitable on an EPS basis with positive cash flow for the full year 2026 without raising additional funds.

Management Comments

• Jon Stonehouse, president and chief executive officer, stated that the company is seeing robust and durable revenue growth, new opportunities for younger children to benefit from ORLADEYO, and data readouts from BCX17725 and avoralstat, all while moving closer to sustainable profitability.
• Charlie Gayer, chief commercial officer, expressed confidence in achieving peak sales of $1 billion for ORLADEYO.
• Dr. Helen Thackray, chief research and development officer, highlighted the progress of the pipeline, with BCX17725 now in the clinic and avoralstat nearing the clinic.
• Anthony Doyle, chief financial officer, noted that BioCryst is in the strongest financial position in its history.

Industry Context

This announcement reflects a positive trend in the rare disease pharmaceutical sector, where companies with successful commercial products and promising pipelines are seeing strong growth and investor interest. BioCryst's focus on oral small-molecule therapies aligns with a broader industry shift towards more convenient and patient-friendly treatments.

Comparison to Industry Standards

• BioCryst's 35.7% year-over-year growth in ORLADEYO revenue is strong compared to other companies in the rare disease space, such as Alexion Pharmaceuticals (now part of AstraZeneca) which has seen growth in the low double digits for its rare disease portfolio.
• The company's move to advance BCX17725 for Netherton syndrome and avoralstat for DME addresses unmet needs in these areas, similar to how companies like Vertex Pharmaceuticals have focused on specific rare diseases with high unmet needs.
• The company's goal to achieve profitability by 2026 is in line with the expectations for biotech companies that have successfully commercialized a product, such as Incyte which achieved profitability after the launch of Jakafi.
• The company's non-GAAP operating profit of $24.9 million is a positive sign, indicating that the company is managing its expenses effectively, similar to how companies like Regeneron have demonstrated strong profitability after successful product launches.

Stakeholder Impact

• Shareholders will likely view the strong financial results and increased guidance positively.
• Patients with HAE will benefit from the continued availability and growth of ORLADEYO.
• Patients with Netherton syndrome and DME may benefit from the development of new treatments.
• Employees may see increased job security and potential for growth due to the company's positive performance.

Next Steps

• The company plans to continue commercializing ORLADEYO and expand its market reach.
• BioCryst will advance BCX17725 into clinical trials and expects initial data in 2025.
• The company plans to advance avoralstat into clinical trials for DME in 2025.
• BioCryst will continue to monitor and manage its operating expenses to achieve profitability.

Key Dates

Keywords

ORLADEYO, BioCryst, Hereditary Angioedema, BCX17725, Avoralstat, Netherton Syndrome, Diabetic Macular Edema, Rare Diseases, Pharmaceuticals, Financial Results